EvolveImmune Therapeutics develops a modular biotherapeutics platform specialized in immuno-oncology.
EvolveImmune Therapeutics has raised $20.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2024.
EvolveImmune Therapeutics's investors include Pfizer, Elm Street Ventures, Yonjin Venture, Takeda Ventures, Solasta Ventures.
EvolveImmune Therapeutics is headquartered in Branford, United States.
EvolveImmune Therapeutics develops a modular biotherapeutics platform specialized in immuno-oncology.
EvolveImmune Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EvolveImmune Therapeutics — Funding & Investors." VCBacked, October 29, 2024, https://www.vcbacked.co/company/evolveimmune-therapeutics. Accessed August 14, 2026.
VCBacked. (2024). EvolveImmune Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/evolveimmune-therapeutics
{{cite web |title=EvolveImmune Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/evolveimmune-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated